CAR-T treatment for certain CD19 or CD70 blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase trial tests a customized immune cell therapy (CAR-T) that targets cancer cells with CD19 or CD70 markers on their surface. It may help your body fight the cancer by directing new immune cells to recognize and attack those cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 6 months old.
- Your cancer must be a B-cell cancer showing CD19 or CD70 on the cell surface.
- Your overall health score must be high (KPS over 80) and you should have more than 1 month of expected survival.
- Your hemoglobin level must be above 80 g/L (enough red blood cells to carry oxygen).
- You need to be able to safely have blood taken for the treatment (blood cell collection not blocked by medical issues).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lab-made immune treatment (CAR-T cells) designed to attack cancer cells that carry CD19 or CD22. It may help people whose B-cell cancers have those markers, provided they meet safety and health requirements.
This trial tests a new type of immune cell therapy (4SCAR19U T cells) designed to attack B-cell cancers. It may be an option if your cancer has the CD19 protein and you haven't had a prior CAR-T treatment that failed.
This trial tests a lab-made immune therapy called CAR-T that targets specific markers on B-cell leukemia/lymphoma cells. It may help people whose cancer has returned or did not respond after earlier CD19 CAR-T, by attacking the cancer cells using added targeting.
This trial studies a type of immune treatment (CAR-T cells) designed to calm overactive immune disease. It may help by aiming the therapy at immune cells involved in B-cell activity, but it has strict health and safety requirements.
This trial tests a new type of CAR-T cell therapy that targets multiple markers on B-cell lymphoma cells. It is for patients whose lymphoma has certain surface markers and who are in reasonably good health.
This early-phase study tests a lab-made immune cell treatment (CAR-T) that targets tumor markers called GD2 and CD70. It is for people whose cancer has spread or returned and cannot be removed by surgery, to see if the treatment can work and how safe it is.
Hear when a new B Cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.